Drug intelligence / Profile preview

UCLG805

Development stage: Preclinical
Lead developer: UTC Therapeutics
Modality: Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

UCLG805 is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by UTC Therapeutics. It is engineered to target glypican-3 (GPC3), a cell-surface oncofetal antigen highly expressed in hepatocellular carcinoma (HCC). The therapy is produced using a lentiviral vector (LVV) and incorporates UTC Therapeutics' proprietary LACO-Stim® technology, which is designed to enhance T-cell stimulation and improve the persistence and efficacy of CAR-T cells against solid tumors. UCLG805 is currently being evaluated in preclinical studies for the treatment of GPC3-positive hepatocellular cancer.

Targets

GPC3 (Glypican-3)

Beyond the preview

Go deeper on UCLG805.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UCLG805.

Explore the full profile